User discusses 4.5 months of using 0.5 DUT & 5 mg Oral Min for hair loss. They share progress pictures and discuss styling options and shedding experiences.
Rating treatments for hair loss, with the help of GPT-4, according to efficacy, evidence and tolerability; a combination of chemicals from research papers, custom compounds, and some suggestions from other users were included.
A user diagnosed with lymphoma is advised to stop finasteride during chemotherapy, with suggestions to consider treatments like Dutasteride and Minoxidil post-recovery. The focus is on prioritizing health over hair loss, with encouragement and advice from others who have experienced similar situations.
People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.
A user reported that after using a topical mix of finasteride and minoxidil, their DHT levels decreased, testosterone and estradiol levels lowered unexpectedly, and they are considering vitamin D3 supplements due to deficiency. They apply the mix 3-4 times a week and use minoxidil on other days. Another user commented that finasteride typically increases testosterone, not decreases it.
GHK-Cu is a potent inhibitor of the type 1 5-alpha reductase enzyme in hair follicles, which may reduce hair loss without the side effects associated with type 2 5-alpha reductase inhibitors. The user previously experienced side effects with 5-alpha reductase inhibitors and is considering GHK-Cu as an alternative.
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
The user experienced side effects from low-dose topical finasteride and is considering using clascoterone (CB-03-01) despite concerns about its risks and cost. They seek advice on its effectiveness and potential side effects compared to other treatments like alfatradiol and fluridil.
The conversation is about whether the phase 2 results for pyrilutamide, a potential hair loss treatment, were presented at a dermatology convention and inquiries about the completion of phase 3 trials. Specific treatments mentioned include pyrilutamide.
MCL-1 protein may help maintain hair follicles in the growth phase and prevent miniaturization. There is interest in experimental treatments like exosomes, peptides, or stem cell serums to upregulate MCL-1 for hair loss, especially for those not using minoxidil or finasteride.
AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.
A 24 year old man suffering from male pattern baldness who has been using minoxidil foam and Redensyl (no longer using) for four months, resulting in general thickening of the hair with some regrowth. The user is also awaiting to get a Finasteride prescription and hormone panel done.
Dutasteride may affect testosterone levels, leading to high ferritin and iron levels, which can cause hair loss. High ferritin might be linked to past heavy drinking or hemochromatosis.
Vitamin D deficiency is linked to hair loss, and supplementation with vitamin D can improve conditions like androgenic alopecia and telogen effluvium. Users discussed various dosages of vitamin D, emphasizing the importance of getting blood tests to determine the appropriate amount.
The conversation discusses the potential effectiveness and future results of the hair loss treatment pp405, with questions about its impact on different hair loss stages and areas. There is anticipation for phase 3 trial results to provide more data, and hope that pp405 could enhance hair transplant outcomes.
The conversation discusses microneedling for hair loss, with the original poster experiencing pinpoint bleeding after using needles of 1.25mm and 0.5mm, possibly due to adding GHK-Cu to their treatment regimen. They are inquiring if others bleed at similar depths.
A 24-year-old is using 1 mg oral dutasteride and 1 mg oral minoxidil daily, along with monthly mesotherapy including zinc, dutasteride, minoxidil, biotin, and panthenol, to treat hair loss. The user is considering increasing the minoxidil dose but will consult with their doctor first.
A 27-year-old man shared his hair regrowth progress after using finasteride for 4 years, recently adding a solution of RU58841 with minoxidil and alfatradiol, tretinoin on temples, and occasional ketoconazole. He is seeking opinions on his treatment approach.
The user reported early stage diffuse hair thinning and increased DHT levels after 4 weeks on Finasteride and 8 weeks on Finasteride plus 4 weeks on Dutasteride, despite the medications being authentic and stored properly. They are considering increasing their Dutasteride dosage due to the lack of side effects and are unsure if the treatment is helping their hair.
The conversation discusses progress with a hair loss treatment regimen that includes once daily topical Finasteride, Pyrilutamide, and WAY-316606. Specific treatments for hair loss are being shared and discussed.
A 36-year-old male experienced significant hair regrowth after four months using a 1mg finasteride and 3mg minoxidil oral pill from Phoenix, alongside lifestyle changes like increased protein intake and exercise. Despite the higher cost of Phoenix, he is hesitant to switch to a cheaper prescription due to successful results.
Pyrilutimide and CB-03-01, two treatments for hair loss, have similar clinical trial results despite different binding affinities to androgen receptors. Factors other than binding affinity, like the time a drug stays bound to the receptor, may influence their effectiveness.
OP noticed fuller and thicker hair after almost 4 months of using GHK-Cu, a copper-binding peptide, through subcutaneous injections. Some users were skeptical, questioning the authenticity and potential commercial intent behind the post.
A 24-year-old shares 4-month progress using finasteride, minoxidil, and microneedling for hair loss. They report positive results and plan to update in a few months.
A user's progress in treating their hair loss with Finasteride, Minoxidil and Dermarolling; they discussed details of their routine and others congratulated them on their success.
The conversation is about dealing with hair loss, with the original poster deciding to start using topical finasteride and minoxidil after unsuccessful PRP and Regenera treatments. Others share their experiences with hair loss, treatments, and the importance of finasteride to prevent further hair loss.
Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.
The user has been using dutasteride for 8 months and added oral minoxidil 1.25mg for 4 months, seeing improved hair density despite minor shedding. They are considering increasing the minoxidil dose to 2.5mg due to concerns about side effects.
A user shared progress pictures showing hairline improvement after 2 years of using topical Minoxidil, 1mg oral Finasteride, and sporadic microneedling. Another user praised the progress and shared mutual encouragement.